Search the Newsreel

AbCellera Biologics Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ABCL) 2026-08-06

This document is AbCellera Biologics' 10-Q filing for its Q2 2026 earnings report. A 10-Q is a comprehensive quarterly report filed by public companies with the SEC, containing unaudited financial performance. It provides a detailed overview of the company's financial condition and results of …

Stifel Nicolaus Issues Positive Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price

AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ...

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbCellera Biologics Inc (NASDAQ:ABCL) completed enrollment for the phase 2 study of ABCL-635 in treating …

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items. This …

Is AbCellera Biologics Inc (ABCL) Facing Headwinds After Q2 Earnings Miss? GF Score: 59/100

AbCellera Biologics Inc (ABCL) reported a significant Q2 2026 earnings miss with revenues of $4.1 million against an estimated $7.78 million and a net loss of $55.4 million. Despite the financial shortfall, the company maintains a strong liquidity position of over $565 million in …

Abcellera Biologics earnings missed, revenue fell short of estimates

AbCellera earnings on deck: Revenue dips as biotech eyes menopause trial

AbCellera Biologics Inc. is preparing to report its second-quarter results, with analysts forecasting a revenue decline despite recent partnership announcements. The company's cash management and the upcoming Phase 2 data readout for its lead menopause drug candidate, ABCL635, are key investor watch points. This …

AbCellera Biologics (NASDAQ:ABCL) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Abcellera Biologics Inc expected to post a loss of 14 cents a share - Earnings Preview

Abcellera Biologics Inc (ABCL) is projected to report a loss of 14 cents per share. This earnings preview is based on Refinitiv data and was published by Reuters.

AbCellera Biologics (ABCL) Signs Vertex Deal, Is The Stock Still Cheap?

AbCellera Biologics (ABCL) has signed a new collaboration with Vertex Pharmaceuticals for autoimmune disease treatments. Despite a recent share price rebound, the stock remains undervalued according to Simply Wall St's narrative, suggesting a fair value of $10.43 compared to its last close of $5.71. …

AbCellera Biologics (ABCL) Is Down 5.9% After Vertex-Backed T-Cell Engager Collaboration Announcement

AbCellera Biologics (ABCL) recently announced a collaboration with Vertex Pharmaceuticals for T-cell engagers, receiving $28 million upfront and potential milestones. This deal, along with a previous one with Jazz Pharmaceuticals, validates AbCellera's technology and provides non-dilutive cash, though the company still faces risks from …

Abcellera Biologics Inc (ABCL) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Abcellera Biologics Inc (ABCL), ranking it 232 out of 384 in the Biotechnology & Medical Research industry with a financial score of 6.64. The company's financial status is weak with low operating efficiency, despite a significant year-over-year …

ABCL|Abcellera Biologics Inc|Price:5.715|Chg%:+0.025

This article provides a comprehensive stock analysis of Abcellera Biologics Inc (ABCL) based on TradingKey's proprietary scoring system. ABCL's fundamentals are described as stable with high growth potential, and its valuation is considered fair within the Biotechnology & Medical Research industry. The report highlights …

ABCL Looks 3.8% Overvalued on GF Value™

AbCellera Biologics Inc (ABCL) is indicated as 3.8% overvalued according to GuruFocus's GF Value™, though its Price-to-Sales ratio is only slightly above historical median. The company, a clinical-stage biotechnology firm, recently partnered with Vertex Pharmaceuticals, receiving a $28 million upfront payment to co-develop multispecific …

Abcellera Biologics Inc (ABCL) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Abcellera Biologics Inc (ABCL), highlighting its beta value of 1.12, indicating higher volatility compared to the S&P 500. The company's risk assessment score is 4.09, ranking it 102 out of 384 in the Biotechnology & Medical Research …

Vertex Pharmaceuticals (VRTX) Expands Its Pipeline Reach, Is The Stock Fully Valued?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Vertex Pharmaceuticals (VRTX) is back in focus after AbCellera Biologics announced a collaboration to develop multispecific T cell engagers targeting autoimmune diseases and …

AbCellera expands multispecific T-cell engager licensing with USD 28m Vertex deal for autoimmune disease

AbCellera Biologics has partnered with Vertex Pharmaceuticals in a deal worth $28 million upfront to discover and develop multispecific T-cell engagers (TCEs) for autoimmune diseases. AbCellera will lead discovery while Vertex retains development and commercialization rights, with AbCellera eligible for milestone payments and royalties. …

AbCellera partners with Vertex on autoimmune therapies

AbCellera Biologics Inc. announced a collaboration with Vertex Pharmaceuticals Incorporated to develop multispecific T-cell engagers for autoimmune diseases. AbCellera will lead discovery and early development, receiving $28 million upfront plus potential milestone payments and royalties, while Vertex funds all R&D and retains commercialization rights. …

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

VANCOUVER, British Columbia, July 29, 2026--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced a collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. "We are excited to collaborate with Vertex, a recognized …

AbCellera Biologics, Inc. Revenue Breakdown – FWB:8QQ

AbCellera Biologics, Inc. (FWB:8QQ) generated €63.97 million last year, primarily from its Antibody Medicines segment. The company's highest revenue contribution geographically came from Canada, accounting for €54.49 million. This report provides a breakdown of the company's financial performance by segment and region for the …

AbCellera Biologics (ABCL) to Post Earnings on Wednesday

Abcellera Biologics Inc (ABCL) Income Statement

This article presents the quarterly and annual income statements for Abcellera Biologics Inc (ABCL), detailing revenues, operating expenses, and net income figures. It provides a comprehensive breakdown of financial performance over several fiscal periods, alongside frequently asked questions to help investors interpret the data. …

ABCL|Abcellera Biologics Inc|Price:5.310|Chg%:-0.360

This article provides a detailed company profile of Abcellera Biologics Inc (ABCL), an antibody discovery and development company. It outlines their business scope, financial data, and market performance, including an overview of their internal pipeline programs and key executive information. The report also lists …

Abcellera Biologics Inc (ABCL) Cash Flow

This article provides a detailed cash flow statement for Abcellera Biologics Inc (ABCL), presenting quarterly and annual data for operating, investing, and financing activities. It includes key metrics like operating cash flow, capital expenditures, and free cash flow, along with definitions and FAQs to …

AbCellera's AI-Driven Pivot: Why Jazz Pharma and ABCL635 Data Signal a New Era for the Biotech

AbCellera Biologics (ABCL) is transforming from an antibody discovery platform to a proprietary drug development company, evidenced by a significant collaboration with Jazz Pharmaceuticals worth up to $876 million and promising interim Phase 1 data for its lead internal program, ABCL635. This strategic pivot …

AbCellera Biologics Market Sentiment

This article provides an overview of AbCellera Biologics (ABCL) market sentiment based on analyst consensus, short interest, options flow, and insider activity. It highlights that analysts have a "Buy" consensus with an average price target of $12, while short interest is rising at 20.6%. …

AbCellera Biologics, Inc. Revenue Breakdown – DUS:8QQ

AbCellera Biologics, Inc. (DUS:8QQ) generated €63.97 million in revenue last year, primarily from its Antibody Medicines segment. This represents a significant increase from €27.85 million in the previous year. The majority of the company's revenue, €54.49 million, originated from Canada.

Abcellera Biologics Inc (ABCL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Abcellera Biologics Inc (ABCL) based on TradingKey's stock score system, which currently ranks its valuation score at 7.22 out of 386 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -11.83, …

ABCL|Abcellera Biologics Inc|Price:5.665|Chg%:-0.065

Abcellera Biologics Inc. (ABCL) is currently trading at $5.475, experiencing a -3.44% decrease. The company's fundamentals are stable with high growth potential, and its valuation is considered fairly valued within the Biotechnology & Medical Research industry. Analysts predominantly rate ABCL as a Buy, with …

Abcellera Biologics, Inc. (8QQ) Q3 2024 Earnings Report - Results, Call & Slides

Abcellera Biologics (8QQ) reported its Q3 2024 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -€0.15 against a consensus of -€0.11 and actual revenue of €5.70M compared to an expected €6.73M. The Q3 2024 earnings call was scheduled …

Does AbCellera’s New Board Appointment Reframe Its Execution Story for Investors in ABCL?

AbCellera Biologics announced the appointment of Lynn Seely, M.D., to its Board of Directors, bringing extensive experience in clinical development and commercialization, particularly in oncology. This appointment is expected to strengthen AbCellera's board-level expertise, aligning with its strategic focus on internal clinical programs and …

Cantor Fitzgerald reiterates Overweight on AbCellera stock at $11

Cantor Fitzgerald has reiterated an Overweight rating and an $11.00 price target for AbCellera Biologics (NASDAQ:ABCL). The firm anticipates positive Phase 2 data for AbCellera's anti-NK3R antibody ABCL635 in Q3 2026, expecting favorable comparisons to approved inhibitors and a significant potential market opportunity. This …

Cantor Fitzgerald reiterates Overweight on AbCellera stock at $11 By Investing.com

Cantor Fitzgerald has reiterated an Overweight rating and an $11 price target on AbCellera Biologics (NASDAQ: ABCL). The firm anticipates positive Phase 2 data for ABCL635, an anti-NK3R antibody for menopausal vasomotor symptoms, expecting favorable comparisons to approved inhibitors and a significant market opportunity. …

JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $13

JonesTrading has reiterated its Buy rating for AbCellera Biologics (ABCL.US), maintaining a target price of $13. This indicates continued confidence from the analyst firm in the company's stock performance.

ABCL Stock Jumps As Earnings Beat And Drug Data Fuel Momentum

Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14